指南与共识临床试验与 GCP新药、器械与细胞基因治疗研发

成人炎症性肠病、炎症性关节炎或银屑病患者生物制剂主动治疗药物监测的临床实践指南

Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline.
指南 / 共识 · BMJ · 2024-10-28

该指南针对使用生物制剂的成人炎症性肠病、炎症性关节炎或银屑病患者,基于纳入10项试验共2383例参与者的系统综述与配对Meta分析,采用GRADE方法制定推荐。推荐对维持期静脉英夫利西单抗进行主动治疗药物监测(弱推荐),对维持期阿达木单抗及其他生物制剂不推荐主动监测(弱推荐),对诱导期所有生物制剂不推荐主动监测(弱推荐)。

要点

  • 维持期静脉英夫利西单抗主动治疗药物监测获弱推荐支持。
  • 维持期阿达木单抗及其他生物制剂不推荐主动治疗药物监测(弱推荐)。
  • 诱导期静脉英夫利西单抗、阿达木单抗及其他生物制剂不推荐主动监测(弱推荐)。

核心结论

  • 对维持期静脉英夫利西单抗弱推荐主动治疗药物监测,对维持期阿达木单抗及其他生物制剂弱推荐不进行主动监测。
  • 对诱导期静脉英夫利西单抗、阿达木单抗及其他生物制剂弱推荐不进行主动治疗药物监测。

研究设计与样本

  • 国际专家组(含患者伙伴、临床医生和方法学家)基于关联系统综述与配对Meta分析制定本临床实践指南。
  • 系统综述与配对Meta分析纳入10项试验,共2383例参与者。
  • 专家组遵循可信赖指南标准并采用GRADE方法,从个体患者角度明确考虑获益与危害及治疗负担的平衡。

主要发现

  • 维持期静脉英夫利西单抗主动治疗药物监测可能增加持续疾病控制或持续缓解的患者比例,且无显著额外危害。
  • 维持期阿达木单抗主动治疗药物监测对持续疾病控制或持续缓解的影响尚不明确。
  • 诱导期静脉英夫利西单抗主动治疗药物监测对达到缓解可能几乎没有影响或没有影响。
  • 诱导期阿达木单抗及其他生物制剂维持期或诱导期主动治疗药物监测均无符合条件的试验证据。

关键数值与推荐

  • 维持期静脉英夫利西单抗:弱推荐支持主动治疗药物监测。
  • 维持期阿达木单抗及其他生物制剂:弱推荐反对主动治疗药物监测。
  • 诱导期静脉英夫利西单抗、阿达木单抗及其他生物制剂:弱推荐反对主动治疗药物监测。

临床怎么用

  • 临床医生与患者考虑主动治疗药物监测时应共同决策,确保患者的选择反映其价值观与偏好。
  • 应考虑实施主动治疗药物监测所需的实验室检测可及性。

局限性

  • 主动治疗药物监测在临床实践中的作用仍不明确,指南推荐存在冲突且随机对照试验证据正在涌现。
  • 维持期阿达木单抗主动治疗药物监测对持续疾病控制或持续缓解的影响尚不明确。
  • 诱导期阿达木单抗及其他生物制剂主动治疗药物监测无符合条件的试验证据。
  • 需进一步研究,未来可能改变推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CLINICAL QUESTION: In adult patients with inflammatory bowel disease, inflammatory arthritis (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis), or psoriasis taking biologic drugs, does proactive therapeutic drug monitoring (TDM) improve outcomes as compared with standard care? CONTEXT AND CURRENT PRACTICE: Standard care for immune mediated inflammatory diseases includes prescribing biologic drugs at pre-determined doses. Dosing may be adjusted reactively, for example with increased disease activity. In proactive TDM, serum drug levels and anti-drug antibodies are measured irrespective of disease activity, and the drug dosing is adjusted to achieve target serum drug levels, usually within pre-specified therapeutic ranges. The role of proactive TDM in clinical practice remains unclear, with conflicting guideline recommendations and emerging evidence from randomised controlled trials. THE EVIDENCE: Linked systematic review and pairwise meta-analysis which identified 10 trials including 2383 participants. Inflammatory bowel disease, inflammatory arthritis, and psoriasis were grouped together as best current research evidence on proactive TDM did not suggest heterogeneity of effects on outcomes of interest. Proactive TDM of intravenous infliximab during maintenance treatment may increase the proportion of patients who experience sustained disease control or sustained remission without considerable additional harm. For adalimumab, it remains unclear if proactive TDM during maintenance treatment has an effect on sustained disease control or sustained remission. At induction (start) of treatment, proactive TDM of intravenous infliximab may have little or no effect on achieving remission. No eligible trial evidence was available for proactive TDM of adalimumab at induction (start) of treatment. No eligible trial evidence was available for proactive TDM of other biologic drugs in maintenance or at induction (start) of treatment. RECOMMENDATIONS: The guideline panel issued the following recommendations for patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis:1. A weak recommendation in favour of proactive TDM for intravenous infliximab during maintenance treatment2. A weak recommendation against proactive TDM for adalimumab and other biologic drugs during maintenance treatment3. A weak recommendation against proactive TDM for intravenous infliximab, adalimumab, and other biologic drugs during induction (start) of treatment. UNDERSTANDING THE RECOMMENDATIONS: When considering proactive TDM, clinicians and patients should engage in shared decision making to ensure patients make choices that reflect their values and preferences. The availability of laboratory assays to implement proactive TDM should also be considered. Further research is warranted and may alter recommendations in the future. HOW THIS GUIDELINE WAS CREATED: An international panel including patient partners, clinicians, and methodologists produced these recommendations based on a linked systematic review and pairwise meta-analysis which identified 10 trials including 2383 participants. The panel followed standards for trustworthy guidelines and used the GRADE approach, explicitly considering the balance of benefits and harms and burdens of treatment from an individual patient perspective.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Kawano-Dourado L, Kristianslund EK, Zeraatkar D, et al. Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline. BMJ. 2024. PMID: 39467592. doi:10.1136/bmj-2024-079830

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。